KAMESHA MOULTRY: Open Payments
NPI 1649727850 · OZARK, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,144 in 54 payments from 10 companies in 2025. Trend: 2023 $89 · 2024 $664 · 2025 $1,144
Food & beverage: $1,144
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $319 |
| Vanda Pharmaceuticals Inc. | 13 | $278 |
| Otsuka America Pharmaceutical, Inc. | 9 | $191 |
| Alkermes, Inc. | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| Janssen Pharmaceuticals, Inc | 3 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Lundbeck LLC | 1 | $15 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: INGREZZA, FANAPT, REXULTI, ARISTADA, AUSTEDO XR, INVEGA SUSTENNA, CAPLYTA, ABILIFY MAINTENA.
Industry payments across AL — which companies pay providers there.
